Medical Xpress
New biosensor detects active tuberculosis in 60 minutes using a fluorescent protein signal
Researchers have developed a biosensor capable of detecting active tuberculosis in just 60 minutes by identifying a protein secreted by Mycobacterium tuberculosis. The device uses a fluorescent protein signal to deliver rapid, selective results at a fraction of the cost of traditional diagnostic methods. This breakthrough could transform TB diagnosis in resource-limited settings, where the disease's weeks-long culture testing timeline often delays critical treatment.
Read article →Medical Xpress
Depression treatment is shifting, and this mushroom-derived compound is driving one of psychiatry's biggest new tests
Psilocybin, the psychoactive compound found in certain mushrooms, is at the center of one of psychiatry's most ambitious clinical trials as researchers explore alternatives to conventional antidepressants. The push comes as SSRIs and SNRIs, while effective for many, leave a significant portion of the estimated 5% of the global population with depression without adequate relief. If trials succeed, psilocybin-assisted therapy could mark the most significant shift in depression treatment in decades.
Read article →Medical Xpress
Weight-loss drugs could tackle Alzheimer's—study
GLP-1 receptor agonists like semaglutide, widely known as weight-loss drugs, may also combat the underlying biology of Alzheimer's disease, according to a new study in Molecular and Cellular Neuroscience. Researchers analyzed 30 preclinical studies examining four drugs in the class — liraglutide, semaglutide, exenatide, and dulaglutide — finding consistent evidence of impact on Alzheimer's pathology. The findings add to a growing body of research suggesting these blockbuster drugs could reshape treatment well beyond metabolic disease.
Read article →Medical Xpress
Discovery of a novel vulnerability in aggressive lymphoma could change future therapy
Researchers at the University of Cologne have identified cFLIP as a key protein that enables Diffuse Large B Cell Lymphoma cells to evade programmed cell death, a major reason current treatments often fail. The finding is particularly significant for ABC-DLBCL, an aggressive subtype with notoriously poor survival rates. Targeting cFLIP could open a new therapeutic avenue for patients with limited options.
Read article →Medical Xpress
Stiffer tumor tissue may accelerate cancer spread and rewire nearby cells
Research from Lund University finds that mechanical stiffness in tumor tissue doesn't just reflect cancer progression — it actively drives it. Stiffer tumors appear to accelerate metastasis while leaving lasting molecular traces in surrounding cells, effectively reprogramming them. The findings deepen understanding of how the physical environment of a tumor shapes cancer behavior, potentially opening new avenues for treatment targeting tissue mechanics rather than genetics alone.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →